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bjectives This study sought to assess the relationship between 1-year mortality and baseline pa-
ient risk in the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute
yocardial Infarction) trial.
ackground The HORIZONS-AMI trial showed that bivalirudin compared with unfractionated heparin
UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) decreased major bleeding and 30-day and 1-year mortality
n patients undergoing primary percutaneous intervention for acute myocardial infarction.
ethods Patients in the HORIZONS-AMI trial were classiﬁed as low, intermediate, and high risk ac-
ording to the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty
omplications) risk score based on 7 clinical variables.
esults Among 2,530 CADILLAC-score evaluable HORIZONS-AMI trial patients, 1,522 (60%) were
lassiﬁed as low risk, 531 (21%) as intermediate risk, and 477 (19%) as high risk. The mortality rates
n the bivalirudin and UFH plus GPI arms, respectively, were 0.4% and 1.2% (p  0.09) in the low-
isk group, 4.2% and 4.1% (p  0.99) in the intermediate-risk group, and 8.4% and 15.9% (p  0.01)
n the high-risk group. Among high-risk patients, there was also a decreased rate of recurrent myo-
ardial infarction in patients randomized to bivalirudin as compared to UFH plus GPI (3.6% vs. 7.9%,
 0.04).
onclusions In high-risk patients undergoing primary percutaneous coronary intervention for acute
yocardial infarction, bivalirudin compared with UFH plus GPI reduces 1-year mortality and recur-
ent myocardial infarction. (HORIZONS-AMI trial; NCT00433966) (J Am Coll Cardiol Intv 2010;3:
96–802) © 2010 by the American College of Cardiology Foundation
rom the *Division of Cardiology Careggi Hospital, Florence, Italy; †Columbia University Medical Center and Cardiovascular
esearch Foundation, New York, New York; ‡Charite–Campus Benjamin Franklin, University Medicine Berlin, Berlin, Germany;
Ospedali Riuniti di Bergamo, Bergamo, Italy; Institute of Internal Medicine, Medical University of Ło´dz´, Ło´dz´, Poland; ¶Moses
one Heart and Vascular Center, Greensboro, North Carolina; #Jagellonian University, Krakow, Poland; **Rabin Medical Center,
etach-Tikva, Israel; and the ††Universitätsklinikum Schleswig-Holstein, Lübeck, Germany. The HORIZONS-AMI trial was
ponsored by the Cardiovascular Research Foundation with unrestricted grant support from Boston Scientific Corporation and The
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797everal studies on primary percutaneous intervention (PCI)
or acute myocardial infarction (AMI) have shown that the
enefit provided by PCI and antithrombotic adjunctive
herapies is related to the risk of the patient, with the benefit
ncreased in high-risk patients (1–3). All effective anti-
hrombotic and anticoagulant adjunctive therapies are asso-
iated with an increased risk of bleeding, and it has been
hown that bleeding complications may have a significant
egative impact on clinical outcome by decreasing or even
See page 803
liminating the anti-ischemic benefit of the antithrombotic
reatment (4,5). In the HORIZONS-AMI (Harmonizing
utcomes with RevasculariZatiON and Stents in Acute
yocardial Infarction) trial, the direct thrombin inhibitor
ivalirudin (Angiomax, The Medicines Company, Parsip-
any, New Jersey) compared with unfractionated heparin
UFH) plus a glycoprotein IIb/IIIa inhibitor (GPI) resulted
n reduced major bleeding, decreased 30-day and 1-year
ortality, and enhanced freedom from net adverse clinical
vents in patients with AMI undergoing primary PCI (6,7).
he aim of this study is to assess the potential relation-
hip between the benefit provided by bivalirudin as com-
ared with UFH plus GPI and the patient risk profile in
he HORIZONS-AMI patient cohort.
ethods
atients. The HORIZONS-AMI trial was a prospective,
pen-label, randomized, multicenter trial that compared
ivalirudin with UFH plus a GPI in patients with ST-
egment elevation AMI undergoing primary PCI. The study
esign and inclusion and exclusion criteria have been re-
orted extensively elsewhere (8). Briefly, consecutive pa-
ients 18 years of age or older who presented within 12 h
fter the onset of symptoms and who had ST-segment
levation AMI of 1 mm or more in 2 or more contiguous
eads, new left bundle-branch block, or true posterior
yocardial infarction (MI) were enrolled in the study. The
tudy was approved by the institutional review board or
thics committee at each participating center, and all pa-
ients gave written informed consent.
tudy protocol and randomization. Patients were randomly
ssigned, in an open-label fashion and in a 1:1 ratio, to
reatment with UFH plus a GPI (the control group) or to
reatment with bivalirudin. Unfractionated heparin was
ees from The Medicines Company, Boston Scientific, and Abbott Vascular. Dr.
tuckey has served on the Speakers’ Bureau and Advisory Board for Boston Scientific.
r. Mehran has received consulting honoraria fees from Abiomed, Abbott Vascular,
ccess Closure, Accumetrics, AstraZeneca, Brocco Diagnostics, Cardiva, Cordis,
aiichi-Sankyo, Eli Lilly, Gilead, Guerbet, The Medicines Company, Regado
iosciences, St. Jude, and Therox and recieves grant support (to Columbia University)dministered as an intravenous bolus of 60 IU/kg of body
eight, with subsequent boluses targeted to an activated
lotting time of 200 to 250 s. Bivalirudin was administered
s an intravenous bolus of 0.75 mg/kg, followed by an
nfusion of 1.75 mg/kg/h. If UFH was administered in a
atient in the bivalirudin group, bivalirudin was started 30 min
ater but in all cases before PCI. Both antithrombin agents
ere discontinued, as specified by the protocol, at the comple-
ion of angiography or PCI but could be continued at low
oses if they were clinically indicated. GPI were administered
efore PCI in all patients in the control group and could be
dministered as provisional treatment in the bivalirudin group
n patients with no reflow after PCI or with giant thrombus.
bciximab or eptifibatide were allowed as GPI at discretion of
he investigator. Aspirin (325 mg given orally or 500 mg
dministered intravenously) was given in the emergency room,
fter which 300 to 325 mg was given orally every day during
he hospitalization and 75 to 81 mg every day thereafter
ndefinitely. A loading dose of clopidogrel (either 300 mg or
00 mg, at the discretion of the investigator), or ticlopidine
500 mg) was administered before
atheterization, followed by 75
g of clopidogrel or 500 mg of
iclopidine every day for at least 6
onths (1 year or longer recom-
ended). Emergency coronary
ngiography was performed after
andomization, followed by triage,
t the discretion of the physician,
o PCI, coronary artery bypass
rafting, or medical management,
s described previously (8).
Two primary end points were
re-specified: major bleeding and
he combined adverse clinical events defined as the combina-
ion of major bleeding or a composite of major adverse
ardiovascular events including death, reinfarction, target vessel
evascularization for ischemia, and stroke. Major bleeding was
efined as intracranial or intraocular hemorrhage, bleeding at
he access site with a hematoma 5 cm in diameter or that
equired intervention, decrease in hemoglobin concentration
4 g/dl without an overt source of bleeding, or 3 g/dl with
n overt source of bleeding, reoperation for bleeding, or blood
roduct transfusion. Major bleeding and the other study end
oint, defined elsewhere, were adjudicated by an independent
linical events committee that was unaware of the treatment
ssignments. Analyses of the primary end points were planned
rom BMS/Sanofi-Aventis. All other authors report that they have no relationships to
isclose.
anuscript received April 27, 2010; revised manuscript received May 20, 2010,
ccepted May 31, 2010.
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
GPI  glycoprotein IIb/IIIa
inhibitors
MI  myocardial infarction
PCI  percutaneous
coronary intervention
UFH  unfractionated
heparin
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798t 30 days and at 1 year. The primary end point of this current
nalysis of the HORIZONS-AMI trial dataset is 1-year
ortality.
aseline patient risk assessment. The CADILLAC (Con-
rolled Abciximab and Device Investigation to Lower Late
ngioplasty Complications) risk score was used to attribute a
isk category to the single patient. The CADILLAC risk score
as been already validated as a prognostic index in patients
ndergoing primary PCI and enables accurate identification of
igh-risk patients as compared with other similar risk scores
or patients with AMI (9,10). Patients were classified as low
score from 0 to 2), medium (score from 3 to 5), and high risk
score6) based on 7 available variables: angiographic baseline
eft ventricular ejection fraction 40% (score 4), renal insuffi-
iency (creatinine clearance60 ml/min) (score 3), Killip class
or 3 (score 3), post-PCI TIMI (Thrombolysis In Myocardial
nfarction) flow grade 3 (score 2), age 65 years (score 2),
nemia (baseline hematocrit level 39% for men, and 36%
or women) (score 2), and 3-vessel coronary artery disease
score 2).
tatistical analysis. Categorical outcomes were compared
y means of the chi-square test or Fisher exact test.
ontinuous variables were compared by means of the
ilcoxon rank sum test. Event rates for each of the risk
lasses (low, medium, and high) were calculated. The
iscriminatory capacity of the model was assessed using
he area under the receiver-operator characteristic curve,
nd the difference between model-predicted and observed
vent rates (goodness-of-fit) was evaluated with the
osmer-Lemeshow test (p  0.05 considered to indicate
ack of deviation between the model and observed rates).
ime-to-event outcomes, determined with Kaplan-Meier
ethods, were compared by means of the log-rank test. For
ll analyses, a 2-sided p  0.05 was considered statistically
ignificant. All statistical analyses were performed by SAS
ersion 8.2 (SAS Institute, Inc., Cary, North Carolina).
esults
ut of 3,602 patients enrolled in the HORIZONS-AMI
rial, 2,530 could be classified by the CADILLAC risk
core. The reasons for patients’ exclusion were as follows:
) baseline left ventricular ejection fraction was not available
n 562 patients; 2) baseline blood samples for hematocrit
nd creatinine values were not drawn in 326 patients; and
) final TIMI flow grade was not assessed by the core lab in
13 patients. Patients excluded from the analysis because of
navailability of 1 or more variables of the CADILLAC
core differed from patients for whom the CADILLAC
core was available in several characteristics. Excluded pa-
ients were more likely to be older and to have anemia and
enal insufficiency, and a post-procedural TIMI flow grade
3 (Table 1). There was no difference in the baseline mlinical characteristics between patients randomized to
ivalirudin or UFH plus GPI and who were considered
or this analysis except for a higher percentage of current
mokers in the bivalirudin arm and hypertensive patients
n the control arm (Table 2). Among the 2,530 evaluable
atients, 1,522 patients (60%) were classified as low risk,
31 patients (21%) as intermediate risk, and 477 patients
19%) as high risk.
-year mortality. There was no difference in follow-up rate
etween patients randomized to bivalirudin (96%) and those
andomized to UFH plus GPI (96.5%). The 1-year mortality
ate was 0.8%, 4.1%, and 12.4% in low-, intermediate-, and
igh-risk patients, respectively (Fig. 1). The CADILLAC risk
core provided an accurate identification of high-risk patients,
nd the area under the receiver-operator characteristic curve
as 0.834 with a Hosmer-Lemeshow value of 0.09. The
ortality rates in patients randomized to bivalirudin or
FH plus GPI were 0.4% and 1.2% in low-risk patients
relative risk [RR]: 0.34, 95% confidence interval [CI]: 0.09
o 1.25, p  0.09), 4.2% and 4.1% in intermediate-risk
atients (RR: 1.00, 95% CI: 0.44 to 2.28, p  0.99), and
.4% and 15.9% in high-risk patients (RR: 0.53, 95% CI:
.32 to 0.89, p  0.01), respectively (Fig. 1). The greatest
enefit in mortality in the high-risk cohort was primarily
ithin the first 2 months, which was then maintained
ver the remainder of the year (Fig. 2). The 1-year
Table 1. Clinical and Procedural Characteristics of Patients With and
Without CADILLAC Risk Score
With
CADILLAC Score
(n  2,530)
Without
CADILLAC Score
(n  1,072) p Value
Age, yrs 60.5 11.4 61.9 12.3 0.0005
Men 1,955/2,530 (77.3) 805/1,072 (75.1) 0.1580
Diabetes mellitus 402/2,530 (15.9) 191/1,069 (17.9) 0.1440
Current smoker 1,196/2,527 (47.3) 456/1,054 (43.3) 0.0260
Hyperlipidemia 1,088/2,530 (43.0) 462/1,069 (43.2) 0.9060
Hypertension 1,339/2,530 (52.9) 585/1,069 (54.7) 0.3230
Prior MI 98/2,530 (3.9) 40/1,072 (3.7) 0.8390
Prior CABG 59/2,530 (2.3) 46/1,069 (4.3) 0.0010
Peripheral vascular disease 104/2,530 (4.1) 56/1,068 (5.2) 0.1320
Body mass index, kg/m2 27.7 4.6 27.5 4.7 0.0320
Killip class 2 208/2,530 (8.2) 97/1,062 (9.1) 0.3710
Symptom onset to PCI, h 5.2 16.4 7.5 58.6 0.8010
Creatinine clearance, ml/min 94.1 34.7 88.3 34.1 0.0001
Creatinine clearance 60 ml/min 383/2,530 (15.1) 171/807 (21.2) 0.0001
Anemia 249/2,530 (9.8) 110/859 (12.8) 0.0150
3-vessel disease 614/2,530 (24.3) 276/1,041 (26.5) 0.1590
LVEF 0.40 348/2,530 (13.8) 98/510 (19.2) 0.0015
Final TIMI ﬂow grade 3 337/2,524 (13.4) 154/947 (16.3) 0.0284
CABG  coronary artery bypass grafting; CADILLAC  Controlled Abciximab and Device Inves-
tigation to Lower Late Angioplasty Complications; LVEF  left ventricular ejection fraction;
MImyocardial infarction; PCI percutaneous coronary intervention; TIMI Thrombolysis in
Myocardial Infarction.ortality rate in the patient group excluded because of
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799navailability of the CADILLAC score (n  1,072) was
% and was identical in the 2 randomization arms (28
eaths in 555 patients randomized to bivalirudin, and 26
Table 2. Baseline Clinical and Angiographic Characte
Plus GPI
All
(n  2,530)
Age, yrs 60.5 11.4
Men 1,955 (77.3%)
Diabetes mellitus 402 (15.9%)
Hypertension 1,339 (52.9%)
Hyperlipidemia 1,088 (43.0%)
Current smoking 1,196 (47.3%)
Prior MI 98 (3.9%)
Prior CABG 59 (2.3%)
Body mass index, kg/m2 27.7 4.6
Symptom onset to PCI, h 5.2 16.4
Killip class 2/4 208 (8.2%)
Creatinine clearance 60 ml/min 383 (15.1%)
Anemia 249 (9.8%)
3 diseased vessels 614 (24.3%)
Anterior infarct location 1,720 (68.0%)
Initial TIMI ﬂow grade 3 337 (13.4%)
LVEF 0.40 348 (13.8%)
Stent implanted 2,471 (97.7%)
Final TIMI ﬂow grade 3 335 (13.2%)
Values presented as n (%) or mean SD unless otherwise noted.
GPI glycoprotein IIb/IIIa inhibitors; other abbreviations as in Table
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Figure 1. Mortality Rates According to Risk Category and Treatment
Mortality rates at 1 year based on CADILLAC (Controlled Abciximab and Devic
low, medium, and high risk in the overall study population and randomized therapyeaths in 517 patients randomized to UFH plus GPI),
hereas bleeding rate was lower in patients randomized to
eparin (5.8% vs. 7.9%, respectively).
s of Patients Randomized to Bivalirudin or Heparin
Bivalirudin
(n  1,245)
Heparin Plus GPI
(n  1,285) p Value
60.2 11.5 60.8 11.4 0.206
971 (78%) 984 (76.6%) 0.396
184 (14.8%) 218 (17.0%) 0.133
630 (50.6%) 709 (55.2%) 0.021
540 (43.4%) 548 (42.6%) 0.712
619 (49.8%) 577 (44.9%) 0.013
44 (3.5%) 54 (4.2%) 0.384
34 (2.7%) 25 (1.9%) 0.191
27.7 4.7 27.7 4.6 0.875
5.5 22.1 5.0 7.5 0.593
103 (8.3%) 105 (8.2%) 0.926
173 (13.9%) 210 (16.3%) 0.086
121 (9.7%) 128 (10.0%) 0.830
304 (24.4%) 310 (24.1%) 0.864
835 (67.1%) 885 (68.9%) 0.331
163 (13.1%) 174 (13.6%) 0.752
155 (12.4%) 193 (15.0%) 0.061
1,221 (98.1%) 1,250 (97.3%) 0.185
166 (13.3%) 169 (13.2%) 0.893
4.2 4.1
RR =1.0
P=0.99
12.4
8.4
15.9
RR =0.53
P=0.01
te-Risk (3-5)
531
High-Risk (≥6)
N=477
 Risk Category
stigation to Lower Late Angioplasty Complications) risk score classiﬁcation ofristic.1
edia
N=
LAC
e Inve
. GPI  glycoprotein IIb/IIIa inhibitors; RR  relative risk.
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800ther clinical events. Table 3 summarizes the clinical events
uring the 1-year follow-up. There were no differences in
onfatal ischemic events between the 2 arms according to
Figure 2. Survival Curves According to Risk Category and Treatment
The rate of death over time by CADILLAC risk score and randomized therapy.
Table 3. 1-Year Event Rates in Patients Randomized to Bivalirudin or
Heparin Plus GPI, According to Risk Category
Bivalirudin
Heparin
Plus GPI p Value Interaction
Death
Low risk 3 (0.4%) 9 (1.2%) 0.087 0.275
Intermediate risk 11 (4.2%) 11 (4.1%) 0.993
High risk 19 (8.4%) 40 (15.9%) 0.0139
Non-CABG major bleeding
Low risk 23 (3.0%) 53 (6.9%) 0.0005 0.311
Intermediate risk 19 (7.2%) 26 (9.8%) 0.281
High risk 29 (12.9%) 45 (17.9%) 0.135
Reinfarction
Low risk 24 (3.2%) 22 (2.9%) 0.723 0.172
Intermediate risk 12 (4.5%) 12 (4.5%) 0.993
High risk 8 (3.6%) 20 (7.9%) 0.042
Stent thrombosis
Low risk 21 (2.8%) 20 (2.6%) 0.834 0.400
Intermediate risk 15 (5.7%) 11 (4.1%) 0.416
High risk 5 (2.2%) 10 (4.0%) 0.275
Target vessel revascularization
Low risk 49 (6.5%) 38 (5.0%) 0.197 0.635
Intermediate risk 27 (10.2%) 16 (6.0%) 0.078
High risk 16 (7.1%) 16 (6.3%) 0.740
Values are presented as n (%) unless otherwise noted. Low risk (n  1,522), intermediate risk
(n 531), and high risk (n 477).nAbbreviations as in Tables 1 and 2.he risk profile except for a higher rate of recurrent MI in
igh-risk patients randomized to UFH plus GPI (7.9% vs.
.6%, p  0.042). Major bleeding rates increased progres-
ively from low-risk to high-risk patients in both random-
zation arms. Major bleeding rates in patients randomized
o bivalirudin were 3% in low-risk patients, 7.2% in
ntermediate-risk patients, and 12.9% in high-risk patients.
he corresponding major bleeding rates in patients ran-
omized to UFH plus GPI were 6.9%, 9.8%, and 17.9%
espectively. Randomization to bivalirudin reduced major
leeding rates in all 3 risk groups; however, the reduction
eached significance in the low-risk patient group only. The
nteraction tests between randomization and risk category
ere statistically not significant for all the considered 1-year
vents (Table 3).
iscussion
he main finding of the present analysis is that in the
ORIZONS-AMI trial the reduction in mortality in
atients randomized to bivalirudin as compared with UFH
lus GPI was mainly driven by a difference in mortality in
he high-risk patient group, whereas no difference could be
evealed in the intermediate-risk group, and only a trend
avoring bivalirudin was revealed in the low-risk group. The
ifference in mortality in the high-risk patient group be-
ween bivalirudin and UFH plus GPI peaked at approxi-
ately 60 days and was maintained at 1-year follow-up.
oreover, in the same high-risk group, randomization to
ivalirudin was associated with a significant decrease in
unfractionated heparin; other abbreviations as in Figure 1.onfatal recurrent MI. Thus, the study results suggest that,
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801t least for hard end points such as death and MI, the extent
f the benefit provided by bivalirudin parallels the risk of the
atient.
As expected, randomization to bivalirudin was associated
ith a decrease in major bleeding. However, this effect was
ot uniformly distributed in the 3 risk categories and was
ore evident in the low-risk patient group, whereas the
ifference in the high-risk group between bivalirudin and
FH and GPI was less pronounced and did not reach
tatistical significance. This finding suggests that the
enefit provided by bivalirudin in terms of death and
ecurrent MI could not be explained solely by the effect
n bleeding. Moreover, stratification of patients according
o the CADILLAC score was able to show a progressive
ncreased risk of major bleeding from low- to high-risk
atients in both randomization arms, confirming that a
orse baseline risk profile is associated with an increased
isk of hemorrhagic complications regardless of the anti-
hrombotic/anticoagulant treatment administered.
Previous studies have shown that periprocedural bleeding
n patients undergoing PCI is associated with an increased
isk of ischemic events and that bleeding adversely affects
hort-term and long-term mortality (4,5). However, in 2
revious trials comparing bivalirudin with UFH plus GPI,
he REPLACE-2 (Randomized Evaluation in PCI Linking
ngiomax to Reduced Clinical Events-2) (11) and ACUITY
Acute Catheterization and Urgent Intervention Triage Strat-
gy) trials (12), the dramatic decrease in bleeding provided by
ivalirudin resulted in only trends and not a statistically
ignificant decrease in mortality. In the ARNO (Antithrom-
otic Regimens aNd Outcome) trial (13) that compared
ivalirudin with UFH in 850 patients pre-treated with 600 mg
f clopidogrel undergoing elective PCI, bivalirudin provided a
ignificant decrease both in bleeding and ischemic complica-
ions (cardiac death, MI, and unplanned target vessel revascu-
arization) and major bleeding was an independent predictor of
schemic events. The analysis in the entire HORIZONS-AMI
atient cohort suggests a strong relation between major bleed-
ng and mortality (6,7). It is possible that the sample size of
ORIZONS-AMI high-risk patients with a CADILLAC
core available is too small to show a significant difference in
erms of bleeding or to avoid the confounding effect of many
ther variables besides the worse baseline risk profile that are
inked to bleeding, such as the dose and duration of an
ntithrombotic treatment, the maintenance of femoral sheath
n PCI patients after the procedure, the cutoff of hematological
arameters used for blood transfusion, or the criteria used for
iscontinuation of antithrombotic treatment. Again, most of
he deaths are not directly due to a fatal bleeding; the link
etween bleeding and mortality is not easily nor fully explained
n most studies; and the mechanism or mechanisms of death
emain largely speculative.
A further possible explanation of the decreased mortality
nd recurrent MI in the high-risk bivalirudin patient groups shown by the current analysis might be linked to the
ntiplatelet effect of bivalirudin that, differently from UFH,
nhibits platelet activation and aggregation (14). However,
his mechanism seems unlikely, considering that this effect
f bivalirudin is widely counterbalanced in the UFH plus
PI arm by the potent platelet aggregation inhibition
rovided by routine administration of GPI. Whatever the
echanism or mechanisms involved in the benefit of biva-
irudin in terms of death and recurrent MI in high-risk
atients, the results of the present analysis support bivaliru-
in treatment as a standard of care for high-risk patients
ndergoing primary PCI for AMI (6).
tudy limitations. This is a non–pre-specified post-hoc,
ubgroup analysis, and the results of the study should be
onsidered hypothesis-generating only. The analysis was
imited to patients with a CADILLAC score available, and
early 30% of patients of the HORIZONS-AMI cohort
ere excluded because of unavailability of the CADILLAC
core. This missing patient percentage may be considered
xpected because the most frequent reason for the exclusion
as the unavailability of the left ventricular angiography;
xcluded patients were older and more frequently had renal
nsufficiency, both markers of increased risk of contrast-
nduced nephropathy. Moreover, the 1-year mortality rate
f 5% in the excluded patient group was identical in the 2
rms, suggesting that a bias effect favoring bivalirudin in the
ubgroup of patients classified as high-risk patients accord-
ng to the CADILLAC score is unlikely. Moreover, the
xpected relatively high percentage of patient exclusion
sing the CADILLAC score is justified by the superior
ccuracy of this score in risk stratification as compared to
ther score systems (10). On the other hand, we must
nderline that some variables of the CADILLAC score are
ot usually available at the time of primary PCI therapy
election. We cannot exclude the play of chance to explain
he revealed difference in mortality between high-risk
atients randomized to bivalirudin and patients random-
zed to UFH plus GPI. However, different from the main
ORIZONS-AMI study, which was not powered for
ortality, the current analysis focused on high-risk pa-
ients who have a very high mortality rate making it
nlikely that the revealed difference is a result of chance.
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